Sarepta Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Sarepta Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Sarepta Therapeutics Inc Strategy Report
- Understand Sarepta Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Sarepta Therapeutics Inc (Sarepta) discovers and develops novel therapeutics based on its RNA technology for the treatment of rare diseases including Duchenne muscular dystrophy (DMD), limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. PMO chemistry is a technology platform, which powers the design and development of novel treatments for rare, infectious, and other diseases. Its RNA technologies include phosphorodiamidate morpholino oligomers (PMOs) and peptide phosphorodiamidate morpholino oligomers (PPMOs). PMO chemistry forms the basis of its technology platform, which powers the design and development of novel treatments for rare, infectious and other diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The R&D of Sarepta focuses on the development of innovative products and discovering, developing, manufacturing, and delivering therapies to patients with rare diseases. In FY2022, Globus spent US$877.09 million on its R&D activities, amounting to 13.7% of the company's total revenue. The company holds numerous issued patents and exclusive rights to issued patents. It has 779 employees that are engaged directly in research and development activities. It also owns and has licenses to various patent applications, in each case in the US and other countries.
Other Break-up
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward